Alkermes
focus and discipline integral to portfolio advancement discovery phase enabling phase phase phase phase alfa intravenous dosing alfa subcutaneous dosing neurology orphan agonist inhibitors neurology neuropsychiatry non orphan inhibitors frontotemporal dementia tumor targeted split inhibitors oncology oncology | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
54 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Results
April 2021
focus and discipline integral to portfolio advancement | Alkermes
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
October 2023
combination programs summary wot | Aeglea BioTherapeutics
Exscientia
Investor Presentation
August 2023
ignite phase initiated in | Exscientia
BioAtla
Investor Presentation
August 2023
summary of dosing regimens for phase clinical studies with cab | BioAtla
Exscientia
Investor Presentation
July 2023
ignite phase initiated in | Exscientia
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io